| Accession |
PRJCA012815 |
| Title |
YLTKL-Ib |
| Relevance |
Medical |
| Data types |
clinical data
|
| Organisms |
Homo sapiens
|
| Description |
To investigate the tolerance of irinotecan hydrochloride liposome injection combined with 5 FU/LV in patients with advanced solid tumors, and recommend the clinical dosage of phase II;To explore the pharmacokinetic characteristics of irinotecan hydrochloride liposome injection combined with 5 FU/LV;Preliminary observation on the efficacy of irinotecan hydrochloride liposome injection combined with 5 FU/LV |
| Sample scope |
patients with advanced solid tumor |
| Release date |
2022-10-27 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
|
|
YLTKL-Ib
|
Phase clinical trial of irinotecan hydrochloride liposome injection combined with 5 FU/LV in the treatment of advanced solid tumors
|
|
|
| Submitter |
binbin
liu (binbin.liu@hengrui.com)
|
| Organization |
jiang su hengrui medicine co,LTD |
| Submission date |
2022-10-27 |
